Great strides have been made in understanding the genetic drivers of cancer, but too many patients still lack effective treatment. Existing therapies target many of the activated oncogenes responsible for tumor growth but do not address the genetic alterations that fuel cancer by inactivating tumor suppressor genes and helping cancer cells evade killing by the immune system. Tango is leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors. Using an approach that starts and ends with patients, Tango is expanding the reach of genetically targeted therapies.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.